Ravi Agrawal Trust, a promoter group entity of Ajanta Pharma , sold 34,50,000 equity shares on June 9, 2026, reducing its stake in the pharmaceutical company. The transaction, executed via the open market, represented 2.76% of the company's paid-up equity share capital. Following the sale, the trust's holding has decreased to 10.24% of the total voting capital.

The disclosures were submitted to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the company filed the necessary details under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing confirmed that the shares sold carried voting rights and that no other instruments such as warrants or convertible securities were involved in the transaction.

Shareholding Details

The table below outlines the changes in the shareholding pattern of Ravi Agrawal Trust following the disposal of shares:

The equity share capital of Ajanta Pharma remains unchanged at ₹ 24,98,71,248, comprising 12,49,35,624 shares of ₹ 2 each. Ravi Agrawal, acting as the trustee of Ravi Agrawal Trust, confirmed the sale in the disclosure addressed to BSE Limited and the National Stock Exchange of India Limited.

Ajanta Pharma witnessed a significant block trade on the National Stock Exchange (NSE), with the transaction valued at ₹400 crore. The deal was executed during the pre-open session, reflecting notable activity at the institutional level in the stock.

Block Trade Details

The following table summarizes the key parameters of the block trade:

The block trade involved approximately 13,47,709 shares of Ajanta Pharma, transacted at a price of ₹2968 per share. Block trades of this scale are typically executed by institutional investors and are carried out outside the regular order book to minimize market impact.